Pediatric prescribing practices and the FDA black-box warning on antidepressants

Journal of Developmental and Behavioral Pediatrics

Volumn 29, Issue 3, 2008, Pages 213-215

  Cheung, Amy ^a,c   Sacks, Diane ^b   Dewa, Carolyn S ^a   Pong, Jessica ^b   Levitt, Anthony ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Community Pediatrician ^*  (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Antidepressant; Depression; FDA black box warning; Pediatricians

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CANADA; CLINICAL PRACTICE; DEPRESSION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; JUVENILE; PEDIATRIC HOSPITAL; PEDIATRICS; POSTAL MAIL; PRESCRIPTION; PRIORITY JOURNAL; SUICIDE; ADOLESCENT; CAUSE OF DEATH; CHILD; CROSS-SECTIONAL STUDY; DRUG LABELING; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FEMALE; LEGAL ASPECT; MALE; MORTALITY; PRACTICE GUIDELINE; STATISTICS; UNITED STATES;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CANADA; CAUSE OF DEATH; CHILD; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; DRUG LABELING; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; MALE; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SEROTONIN UPTAKE INHIBITORS; SUICIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 49649125181     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/DBP.0b013e31817bd7c9     Document Type: Article

References (12)

1. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRI's. Am J Psychiatry. 2007;164:884-891.
2. Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med. 2007;161:690-696.
3. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006;163:1898-904.
4. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007; 164:1356-1363.
5. Hamilton BE, Minino AM, Martin JA, et al. Annual summary of vital statistics: 2005. Pediatrics. 2007;119:345-360.
6. Bridge JA, Lyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. JAMA. 2007;297:1683-1696.
7. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003;60:978-982.
8. Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry. 2004;65:915-918.
9. Gray D, Moskos M, Keller T. Utah Youth Suicide Study New Findings. Presented at the annual meeting of the American Association of Suicidology Sante Fe, New Mexico 2003.
10. Lineberry TW, Bostwick JM, Beebe TJ, et al. Impact of FDA Black Box Warning on physician antidepressant prescribing and practice patterns: Opening Pandora's suicide box. Mayo Clin Proc. 2007;82:516-522.
11. Olson AL, Kemper KJ, Kelleher KJ, et al. Primary care pediatricians' roles and perceived responsibilities in the identification and management of maternal depression. Pediatrics. 2002;110:1169-1176.
12. Olson AL, Kelleher KJ, Kemper KJ, et al. Primary care pediatricians' roles and perceived responsibilities in the identification and management of depression in children and adolescents. Ambul Pediatr. 2001;1:91-98.